☆ 4.7 Article

Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 A Randomized Controlled Trial

ANNALS OF INTERNAL MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, General & Internal

Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels A Randomized Controlled Trial

J. D. Lundgren et al.

Summary: The study aimed to evaluate the efficacy and safety of bamlanivimab in COVID-19 patients, with results indicating potential benefits in patients without neutralizing antibodies at baseline. However, due to the limited sample size, further research is needed to assess the effects of other types of passive immune therapies in the same patient setting.

ANNALS OF INTERNAL MEDICINE (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)

Daniel D. Murray et al.

Summary: This study presents a multi-stage clinical trial protocol for treating COVID-19 inpatients globally, aiming to evaluate the safety and efficacy of various novel antiviral drugs. Through multi-network partnerships, the protocol successfully achieved rapid assessment of candidate drugs and the generation of efficacy data. Implementation faced challenges such as ensuring drug supply, reliable recruitment, and regulatory approvals across global sites.

CLINICAL TRIALS (2022)

添加到收藏夹

Article Medicine, General & Internal

Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection A Randomized Clinical Trial

Meagan P. O'Brien et al.

Summary: This study evaluated the effect of subcutaneous casirivimab and imdevimab on progression from asymptomatic SARS-CoV-2 infection to symptomatic COVID-19. The results showed that this combination treatment significantly reduced the incidence of symptomatic COVID-19, as well as the duration of symptoms and viral load.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

添加到收藏夹

News Item Medicine, General & Internal

Nature does things well

[Anonymous]

EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)

添加到收藏夹

Article Infectious Diseases

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

Wesley H. Self et al.

Summary: This study assessed the efficacy and safety of two neutralising monoclonal antibody therapies for adults hospitalised with COVID-19. The results showed that neither of the therapies showed significant improvement in clinical outcomes among COVID-19 patients.

LANCET INFECTIOUS DISEASES (2022)

添加到收藏夹

Letter Medicine, General & Internal

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

Emi Takashita et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Critical Care Medicine

Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

Hugh Montgomery et al.

Summary: This study evaluated the safety and efficacy of tixagevimab-cilgavimab in preventing severe COVID-19 or death in non-hospitalized adults. The results showed that a single dose of tixagevimab-cilgavimab significantly reduced the risk of progression to severe COVID-19 or death, with favorable safety.

LANCET RESPIRATORY MEDICINE (2022)

添加到收藏夹

Article Critical Care Medicine

Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase atrial

Thomas L. Holland et al.

Summary: This study compared the efficacy of tixagevimab-cilgavimab with placebo in hospitalized COVID-19 patients receiving remdesivir and standard care. The results showed that tixagevimab-cilgavimab did not improve sustained recovery, but it was safe and associated with lower mortality.

LANCET RESPIRATORY MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

Summary: In a platform trial involving patients hospitalized with Covid-19, among 314 patients who were also being treated with remdesivir, those who received the monoclonal antibody LY-CoV555 did not have better pulmonary function at day 5 than those who received placebo. The trial was stopped for futility.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen et al.

Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: REGEN-COV reduced the risk of Covid-19-related hospitalization or death, resolved symptoms, and reduced the SARS-CoV-2 viral load more rapidly than the placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Anil Gupta et al.

Summary: In this study, among nonhospitalized patients with symptomatic Covid-19, sotrovimab treatment significantly reduced the risk of disease progression leading to hospitalization or death compared to placebo. Patients receiving sotrovimab also had a lower rate of serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities

Myron S. Cohen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

M. Dougan et al.

Summary: In this phase 3 trial, the combination of bamlanivimab plus etesevimab was found to reduce the incidence of Covid-19-related hospitalization and death among high-risk ambulatory patients compared to placebo, and also accelerated the decline in SARS-CoV-2 viral load.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Oncology

Beyond Antibodies: The DARPin®Drug Platform

Michael T. Stumpp et al.

BIODRUGS (2020)

添加到收藏夹

Article Infectious Diseases

A minimal common outcome measure set for COVID-19 clinical research

J. C. Marshall et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Critical Care Medicine

Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial

Richard T. Davey et al.

LANCET RESPIRATORY MEDICINE (2019)

添加到收藏夹

Article Biotechnology & Applied Microbiology

High-affinity binders selected from designed ankyrin repeat protein libraries

HK Binz et al.

NATURE BIOTECHNOLOGY (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.